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We tested the hypothesis that inhibition of Epstein–Barr virus (EBV) reactivation is controlled in part by nitric oxide (NO)
generated from L-arginine (Arg). The spontaneous reactivation of EBV in the Burkitt’s lymphoma (BL) cell line P3HR-1 was
inhibited when the cells were cultured in L-Arg-supplemented medium. The expression of EBV early antigen (EA), immediate-
early BZLF1 mRNA and the protein ZEBRA, and production of infectious virus were reduced by L-Arg supplementation in a
dose-dependent manner. We demonstrated that inducible NO synthase (iNOS) mRNA was constitutively expressed in P3HR-1
cells, as quantitated by the reverse transcription-polymerase chain reaction. L-Arg supplementation enhanced iNOS and NOx
expression in the cells. A specific NOS inhibitor, NG-monomethyl-L-Arg enhanced the expression of ZEBRA and early BMRF1
protein EA-D in the cells. L-Arg supplementation also inhibited the spontaneous EBV reactivation in another BL cell line EB1INTRODUCTION
Epstein–Barr virus (EBV) is a human herpesvirus that
causes infectious mononucleosis and is associated with
various lymphoid and epithelial malignancies (Rickinson
et al., 1996), for example, Burkitt’s lymphoma (BL) and
nasopharyngeal carcinoma (Pathmanathan et al., 1995).
EBV establishes latent infection in EBV-infected cell lines
and is reactivated in the infected cells by compounds
such as neocarcinostatin (Sairenji and Hinuma, 1970),
5-bromodeoxyuridine (Gerber, 1972; Hampar et al., 1972),
5-iododeoxyuridine (Sugawara and Osato, 1973), 12-O-
tetradecanoylphorbol-13-acetate (TPA) (zur Hausen et al.,
1978), n-butyrate (Luka et al., 1979), and TGF-1 (Fukuda
et al., 2001) or by cross-linking of surface immunoglob-
ulin (Takada, 1984). These agents activate expression of
the viral immediate-early protein BZLF1, which is also
termed ZEBRA, EB1, Zta, or Z, and triggers the EBV-
reactivation cascade in the cells (Countryman and Miller,
1985; Chevallier-Greco et al., 1986; Takada et al., 1986;
Flemington and Speck, 1990). Recently it was reported
that the EBV reactivation cascade by these lytic cycle-
inducing agents is associated with cell-cycle progres-
sion (Rodriguez et al., 2001).
P3HR-1, a BL cell line, has spontaneous EBV reactiva-
tion in a small fraction of the cells and has been widely
used as one of the stable EBV producer cell lines in vitro.
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114EBV reactivation is more efficient in cultures with L-Arg-
deficient medium (Henle and Henle, 1968) or in cultures
at 33°C than at 37°C (Hinuma et al., 1967; Konn et al.,
1969; Weinberg and Becker, 1969; Nagoya and Hinuma,
1972; Sairenji and Hinuma, 1975, 1980; Sairenji et al.,
1985). The EBV from P3HR-1 cells differs from other EBV
isolates: for example, it cannot transform B lymphocytes
into lymphoblastoid cell lines (Sairenji and Hinuma,
1980). The virus induces a lytic cycle in EBV-carrying
lymphoblastoid cell lines as signaled by the appearance
of the early antigen (EA) complex in the EBV infected
cells by the immunofluorescence technique (Henle et al.,
1971). Two distinct patterns of EA immunofluorescence
were demonstrated, discriminating, respectively, EA-D
and EA-R (Henle et al., 1971). EA-D and EA-R are asso-
ciated with EBV DNA polymerase (Tsurumi et al., 1996)
and with a subunit of an EBV-encoded ribonucleotide
reductase (Goldschmidts et al., 1989). Spontaneous EBV
reactivation in P3HR-1 cells is induced by a heteroge-
neous virus with WZ het EBV DNA (Heston et al., 1982;
Miller et al., 1985). The EBV lytic cycle or EBV production
in the infected cells is modulated by bovine serum
(Sairenji and Hinuma, 1975; Hinuma et al., 1980; Matsu-
moto et al., 1980), by EBV-positive human serum (Sairenji
et al., 1991), by anti-gp350/220 monoclonal antibodies
(Sairenji et al., 1985, 1988), and by nitric oxide (NO)
(Mannick et al., 1994; Kawanishi, 1995; Gao et al., 1999,
2001).
Previously we have studied the mechanism of theand a B lymphoblastoid cell line OB. These results indicate
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epithelial cell lines GT38 and GT39 (Gao et al., 1999,
2001). NO is an important signaling molecule regulat-
ing a wide array of biological activities in neural,
vascular, and immune cells (Nathan, 1992). NO is
generated from L-Arg in the presence of the enzyme
NOS (Moncada et al., 1991), which includes three
different isoformers: neuronal (nNOS, NOS1), induc-
ible (iNOS, NOS2), and endothelial (eNOS, NOS3).
These isoforms are expressed in a wide range of cell
types and tissues (Nathan and Xie, 1994; Wang et al.,
1997). iNOS was first described in macrophages stim-
ulated with interferon-gamma (IFN-) or bacterial lipo-
polysaccharide (Stuehr and Marletta, 1985), but later it
was also found that iNOS can also be expressed in
additional cell types including hepatocytes, endothe-
lial cells, and smooth muscle cells (Palmer et al., 1988;
Nathan and Hibbs, 1991). In particular, IFN--induced
NO production by macrophages has been implicated
in resistance to intracellular pathogens, such as par-
asites (Stenger et al., 1994), fungi (Nakamura et al.,
1994), mycobacteria (Flesch et al., 1994), and viruses,
such as ectromelia virus (Karupiah et al., 1993), vac-
cinia virus (Harris et al., 1995), Friend leukemia virus
(Akarid et al., 1995), herpes simplex virus type 1
(Croen, 1993), and murine hepatitis virus type 3 (Pope
et al., 1998).
In seeking to investigate the effect of NO on EBV
reactivation, we considered the interesting observa-
tion that L-Arg-deficient medium promotes EBV repli-
cation in EBV-infected BL cell lines (Henle and Henle,
1968; Weinberg and Becker, 1969; Hampar et al., 1976),
although L-Arg is required for replication of herpes
simplex virus (Pelmont and Morgan, 1959; Tankersley,
1964) and other members of the herpes group (Bayliss
and Wolf, 1982). Henle and Henle speculated that
Arg-deficient media might promote the EBV infection
indirectly, by reducing intracellular inhibitors for EBV
infection on reducing cellular replication (Henle and
Henle, 1968). However, a mechanism for enhancing
EBV reactivation had not been offered until now. We
hypothesize that the EBV reactivation is induced by
reduced intracellular NO in cells cultured in L-Arg-
deficient medium, because NO inhibits EBV reactiva-
tion in EBV-infected B cells (Mannick et al., 1994;
Kawanishi, 1995) and in epithelial cell lines (Gao et al.,
1999, 2001) and NO is a metabolic product from L-Arg
(Stuehr and Marletta, 1985; Moncada et al., 1991).
In this study we analyzed the effect of L-Arg supple-
mentation instead of L-Arg-deficient medium on sponta-
neous EBV reactivation in P3HR-1 cells, because L-Arg-
deficient medium leads to cell death. We investigated
whether L-Arg supplementation inhibits EBV reactivation
in P3HR-1 cells, whether P3HR-1 cells express iNOS
mRNA and end products NOx, and whether iNOS mRNA
expression and reduction of EBV reactivation are corre-
lated. We found that spontaneous EBV reactivation in
P3HR-1 cells was inhibited with L-Arg supplementation
and the inhibition of EBV reactivation correlated with
iNOS mRNA expression induced by L-Arg supplementa-
tion.
RESULTS
Effect of L-Arg on cell growth and EA expression in
P3HR-1 cells
The effect of L-Arg on growth of P3HR-1 cells was
tested in cultures grown at 37 or 33°C (Fig. 1). Total
viable cell number was larger at 33°C than at 37°C. Cell
growth increased in a dose-dependent manner to the
concentration of L-Arg, but the dose-dependency was
not observed in 0.4 and 0.7 mM L-Arg at 33°C.
The percentage of EA-positive cells was significantly
higher in cells grown at 33°C than at 37°C. The percent-
age of EA-positive cells decreased in proportion to the
L-Arg concentration; however, the dose-dependency was
not observed between 0.4 and 0.7 mM L-Arg. These
results indicated that EBV is reactivated more efficiently
at 33°C than at 37°C and that L-Arg promotes cell growth
and reduces EBV reactivation in the cells either at 37 or
33°C.
FIG. 1. Effect of L-Arg on cell growth and EBV reactivation in P3HR-1
cells. P3HR-1 cells were cultured in medium with various concentra-
tions of L-Arg (F 0.4, E 0.7, Œ 0.9, ‚ 1.2 mM) at 37 or 33°C. Viable cells
were counted by the trypan blue dye exclusion method. Percentages of
EA-positive cells were determined by an immunofluorescence tech-
nique.
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Effect of L-Arg on the expression of EBV immediate-
early BZLF1/BRLF1 genes
The EBV lytic infection is initiated by expression of
the BZLF1 gene in EBV-infected B cells (Countryman
and Miller, 1985; Chevallier-Greco et al., 1986; Takada
et al., 1986). We examined the induction of both BZLF1/
BRLF1 mRNAs (Fig. 2A) and the BZLF1 protein product
ZEBRA (Fig. 2B) in the P3HR-1 cells by Northern and
Western blotting analyses, respectively. The BZLF1
and BRLF1 genes were expressed as 1.0- and 3.0-kb
FIG. 2. Effect of L-Arg on the expression of EBV immediate-early genes BZLF1 and BRLF1, the protein product ZEBRA, and the production of
infectious virus. P3HR-1 cells were cultured in medium with various concentrations of L-Arg at 37 or 33°C. (A) Total RNAs of P3HR-1 cells were
extracted at 7 days after incubation. Northern blotting was performed with a BZLF1 probe. The same blot was stripped with stripping buffer and
rehybridized with a probe for GAPDH. The autoradiographs for BZLF1 and GAPDH mRNAs were analyzed by laser densitometry and the RNA levels
of BZLF1 were normalized to the corresponding GAPDH signals (right). (B) The proteins of P3HR-1 cells were extracted at 7 days after incubation,
separated electrophoretically, blotted onto membranes, and immunoreacted with anti-ZEBRA monoclonal antibodies. Twenty (at 33°C) and thirty (at
37°C) micrograms of protein were loaded on the gels. The autoradiograph was analyzed for ZEBRA band intensities by laser densitometry (right). (C)
Effect of L-Arg on the production of infectious EBV. P3HR-1 cells were cultured in the presence of various concentrations of L-Arg (F 0.4, E 0.7, Œ
0.9, ‚ 1.2 mM) at 37°C. The EA inducing activity of P3HR-1 culture supernatants on Raji cells was assayed at indicated time points. The infectious
titers were indicated as EAIU/ml.
116 AGAWA ET AL.
mRNA, respectively, and their expression levels were
higher at 33°C than at 37°C. BZLF1 and BRLF1 ex-
pressions decreased in the cells cultured in medium
supplemented with L-Arg in a dose-dependent man-
ner, both at 37 and 33°C. ZEBRA expression also
decreased as a function of L-Arg concentration in a
dose-dependent manner, at both 37 and 33°C. The
reduction of BZLF1/BRLF1 RNAs and ZEBRA expres-
sion was more distinctive at 37°C than at 33°C.
To examine further the effect of L-Arg on infectious virus
production, P3HR-1 cells were cultured at 33°Cwith 0.4, 0.7,
0.9 or 1.2 mM L-Arg (Fig. 2C). The infectious virus titers
(EAIU/ml) in culture supernatants were assayed at days 2,
4, 6, and 8. The titers decreased as a function of increasing
L-Arg in a dose-dependent manner.
iNOS gene expression in P3HR-1 cells
To test whether P3HR-1 cells express iNOS mRNA, we
performed RT-PCR and Southern blotting (Fig. 3A). iNOS
FIG. 3. Effect of L-Arg on the expression of iNOS mRNA. (A) P3HR-1 cells constitutively express iNOS mRNA. cDNA was made from total RNAs of
P3HR-1 and GT38 cells which express iNOS mRNA (Gao et al., 1999). Samples to which reverse transcriptase was (RT) or was not (RT) added
are indicated. Equal amounts of each sample were PCR-amplified using primers specific for either human iNOS or tubulin, and the PCR products were
analyzed by Southern blotting. The autoradiographs for iNOS and tubulin mRNAs were analyzed by laser densitometry and the levels of iNOS mRNA
were normalized to the corresponding tubulin signals (right). (B) Total RNAs from P3HR-1 cells were extracted at 5 days (top) and 7 days (bottom) after
incubation and were analyzed for iNOS mRNA expression by RT-PCR, Southern blotting. The autoradiographs for iNOS and tubulin mRNAs were
analyzed by laser densitometry and the RNA levels of iNOS were normalized to the corresponding tubulin signals (right).
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mRNA was detected at the size (729 bp) of the ampli-
fied product in positive control GT38 cells (Gao et al.,
1999) and in P3HR-1 cells. The iNOS mRNA expression
level in P3HR-1 cells was about 50% that of GT38 cells.
We failed to detect iNOS mRNA by Northern blotting
analysis (data not shown), indicating that the expression
level was low.
To investigate the effect of L-Arg on iNOS mRNA ex-
pression, the expression of iNOS mRNA was analyzed
on day 5 and day 7 in P3HR-1 cells cultured in medium
with various concentrations of L-Arg (Fig. 3B). The ex-
pression of iNOS mRNA was higher in cells cultured at
37°C than in cells cultured at 33°C. iNOS mRNA expres-
sion increased gradually as a function of L-Arg concen-
tration in a dose-dependent manner, in cells cultured at
either 37 or 33°C.
NOx production in P3HR-1 cells
To confirm NO production in P3HR-1 cells, we mea-
sured the NO metabolites, NOx (Fig. 4). P3HR-1 cells
were cultured in medium containing 1.2 mM L-Arg or 1.2
mM L-lysine (Lys) as a negative control at either 37 or
33°C. The amounts of NOx increased as a function of
L-Arg supplementation at 37°C in a time-dependent
manner. There was, nevertheless, some increase in
amounts of NOx in cells cultured at 33°C. Overall, NOx
levels were higher in cells cultured at 37°C than in 33°C
cells.
Induction of EBV reactivation by a specific
competitive inhibitor of NOS, L-NMMA
To test further our hypothesis of a causal relationship
between NO concentration and inhibition of EBV reacti-
vation, we analyzed the effects of NG-monomethyl-L-Arg
(L-NMMA), a specific competitive inhibitor of NOS on
EBV reactivation in P3HR-1 cells (Fig. 5). The cells were
pretreated with L-NMMA (0, 0.5, or 5 mM) for 1 h and
then cultured in 1.2 mM L-Arg medium at 37 or 33°C.
L-NMMA inhibited cell growth in a dose-dependent man-
ner (Fig. 5A). Five millimolar of L-NMMA enhanced the
FIG. 4. Effect of L-Arg on NOx production. P3HR-1 cells were cultured
in medium with L-Arg (1.2 mM) or L-Lys (1.2 mM) at 37 or 33°C for
indicated times. The amounts of NOx (NO2
  NO3
) released from
P3HR-1 cells were measured by the method of Griess.
FIG. 5. Effect of L-NMMA on P3HR-1 cell growth and EBV reactiva-
tion. P3HR-1 cells were pretreated with or without L-NMMA (E 0, F 0.5,
Œ 5 mM) for 1 h and cultured in medium with 1.2 mM L-Arg at 37 or
33°C. (A) Cell growth was counted by trypan blue dye exclusion
method. EA-positive cells were determined by the indirect immunoflu-
orescence. (B, C) The proteins were extracted from the cells at 3 days
(37°C; left) and 5 days (33°C; right), respectively, after addition of L-Arg,
separated electrophoretically blotted onto membranes, and then im-
munoreacted with anti-ZEBRA and EA-D monoclonal antibodies, re-
spectively. Twenty (at 33°C) and thirty (at 37°C) micrograms of proteins
were loaded in the wells. The autoradiograph for the intensities of
ZEBRA and EA-D bands were analyzed by laser densitometry (bottom).
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EA expression in the cells at 37 and 33°C. No effect on
EA expression was detected with 0.5 mM L-NMMA.
ZEBRA expression was enhanced in 5 mM L-NMMA at
37 and 33°C (Fig. 5B). The level of BMRF1 product EA-D,
an antigen complex expressed in the early phase of the
EBV lytic cycle, was markedly increased at 37 and 33°C
with 5 mM L-NMMA (Fig. 5C). These results indicated
that latent EBV in P3HR-1 cells could be reactivated by
L-NMMA, which blocks iNOS and is consistent with a
conclusion that EBV reactivation is inhibited by NO.
Effect of L-Arg on the EBV reactivation in the other
EBV infected cell lines
To extend the generality of down-regulation of EBV
reactivation by L-Arg for other infected cell lines, we
examined the effect of L-Arg on spontaneous EBV reac-
tivation in the EBV-positive BL cell line EB1 (Epstein and
Barr, 1964, 1965) and an EBV-positive lymphoblastoid B
cell line OB derived from peripheral blood mononuclear
cells of a patient with atopic dermatitis (Ohnishi et al.,
1997; Fukuda et al., 2001). EB1 and OB cells were cul-
tured in medium with 0.4 or 1.2 mM L-Arg for 5 days at
37°C. The induction of BZLF1/BRLF1 mRNAs and ZEBRA
was analyzed in these cells by Northern and Western
blotting analyses, respectively (Fig. 6). BZLF1 (Fig. 6A)
and ZEBRA (Fig. 6B) expressions clearly decreased in
EB1 and OB cells in medium supplemented with L-Arg in
a dose-dependent manner. iNOS mRNA expression in-
creased as a function of L-Arg concentration in a dose-
dependent manner in those cells (Fig. 6C). These results
generalized that spontaneous EBV reactivation is inhib-
ited in EBV-infected cell lines by L-Arg supplementation.
DISCUSSION
In this study, we found that adding L-Arg to cultures of
P3HR-1 cells promotes cell growth and inhibits sponta-
neous EBV reactivation. We demonstrated that a low
level of iNOS mRNA is constitutively expressed in
P3HR-1 cells and that the levels of iNOS are enhanced
by L-Arg supplementation in a dose-dependent manner,
while the EBV reactivation was correspondingly reduced.
NO metabolites, NOx (NO2
 and NO3
), are increased by
L-Arg supplementation. A specific NOS inhibitor,
L-NMMA, enhanced EBV reactivation in the cells. These
results are consistent with a conclusion that NO is syn-
thesized in P3HR-1 cells by iNOS from the L-Arg sub-
strate and that synthesized NO then inhibits EBV reacti-
vation in those cells. Our data support this proposed
mechanism that the original observation of EBV reacti-
vation in L-Arg-deficient medium by Henle and Henle
(1968) is due to the reduction of intracellular NO which
inhibits EBV reactivation (Mannick et al., 1994; Kawa-
nishi, 1995; Gao et al., 1999, 2001). This is the first article
showing that addition of L-Arg to cultures induces iNOS
synthesis in P3HR-1 cells and further systematically test-
FIG. 6. Effect of L-Arg on the expression of BZLF1 mRNA, ZEBRA,
and iNOS mRNA. EB1 and OB cells were cultured in medium with 0.4
or 1.2 mM L-Arg for 5 days at 37°C. (A) Total RNAs of both cells were
extracted and Northern blotting was performed with a BZLF1 probe.
The same blot was stripped with stripping buffer and rehybridized
with a probe for GAPDH. The autoradiographs for BZLF1 and
GAPDH mRNAs were analyzed by laser densitometry and the RNA
levels of BZLF1 were normalized to the corresponding GAPDH
signals (bottom). (B) The proteins of both cells were extracted,
separated electrophoretically, blotted onto membranes, and immu-
noreacted with anti-ZEBRA monoclonal antibodies. Forty micro-
grams of protein were loaded on the gels. The autoradiograph was
analyzed for ZEBRA band intensities by laser densitometry (bottom).
(C) Total RNAs from both cells were extracted and were analyzed for
iNOS mRNA expression by RT-PCR, Southern blotting. The autora-
diographs for iNOS and tubulin mRNAs were analyzed by laser
densitometry and the RNA levels of iNOS were normalized to the
corresponding tubulin signals (bottom).
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ing the hypothesis that a causal relationship exists be-
tween intracellular NO and inhibition of EBV reactivation.
We demonstrated that iNOS mRNA is expressed con-
stitutively in P3HR-1 cells and is enhanced in such cells
by L-Arg supplementation. The induction of iNOS mRNA
offers a mechanism to explain the phenomenon termed
“Arg paradox” (Forstermann et al., 1994; Kurz and Harri-
son, 1997). The term Arg paradox was used to refer to
situations in which exogenous L-Arg administration
seems to drive enzyme activity of iNOS, even when levels
of L-Arg are present in excess. L-Arg is the substrate of
iNOS and is metabolized to NO (Moncada et al., 1991).
We used DMEM, which contains only a limiting level of
L-Arg (0.4 mM), and supplemented with L-Arg to a final
concentration of 0.7, 0.9, or 1.2 mM. iNOS was induced in
the P3HR-1 cells by L-Arg in a dose-dependent manner.
RPMI 1640 medium that is commonly used for lymphoid
cell culture contains 1.2 mM L-Arg. These data show that
induction of iNOS and suppression of EBV reactivation
are clearly controlled with small changes in the concen-
tration of L-Arg in the medium.
Spontaneous EBV reactivation in EBV-positive cell
lines occurs in a more tightly efficient fashion at 33°C
culture conditions than that at 37°C (Hinuma et al., 1967;
Weinberg and Becker, 1969; Konn et al., 1969; Nagoya
and Hinuma, 1972; Sairenji and Hinuma, 1975, 1980;
Sairenji et al., 1985). Cultivation at 33°C has been pre-
ferred for studies of intracellular EBV synthesis and for
the effective EBV production in EBV-infected cell lines.
However, the mechanism of temperature dependence in
EBV reactivation has not been explained well. We dem-
onstrated that the levels of iNOS mRNA and NOx are
always higher in cells cultured at 37°C than those at
33°C and the EBV reactivation occurs in an inverse
correlation to expression of iNOS mRNA and NOx. These
results confirm the view that because NO is produced
more highly at 37°C than at 33°C, therefore, EBV reac-
tivation occurs more efficiently at 33°C than at 37°C.
We have studied several mechanisms which modulate
EBV production in P3HR-1 cells. Previous reports showed
inhibition of EBV release by an antivirus release factor,
which is present in both bovine serum (Sairenji and Hi-
numa, 1975; Matsumoto et al., 1980) and normal human
serum (Hinuma et al., 1980). Then we reported that EBV
release from P3HR-1 and B95-8 cells is inhibited by mono-
clonal antibodies to EBV membrane antigen gp350/220,
which do not have neutralizing activity (Sairenji et al., 1985,
1988). We also reported that culturing cells with EBV-sero-
positive but not EBV-seronegative human sera reduce both
production of infectious virus and amounts of virion DNA in
the cells and the supernatants (Sairenji et al., 1991). These
studies indicated that the EBV production in P3HR-1 cells is
modulated by EBV-specific and -nonspecific factors. In the
current study, we have further demonstrated that EBV re-
activation in P3HR-1 cells is modulated by L-Arg in gener-
ating NO.
It is predictable that a role for NO inhibition of EBV
reactivation is common among EBV-infected cells re-
gardless of cell types, given the evidence for iNOS ex-
pression and the inhibition of EBV reactivation in EBV-
infected B cells (Mannick et al., 1994) and epithelial cells
(Gao et al., 1999, 2001). In this study we demonstrated
that L-Arg supplementation down-regulates spontane-
ous EBV reactivation in BL cell lines P3HR-1 and EB1 and
a B lymphoblastoid cell line OB. EBV reactivation from
latency is initiated by BZLF1 gene expression (Country-
man and Miller, 1985; Chevallier-Greco et al., 1986;
Takada et al., 1986). NO could directly or indirectly down-
regulate expression of EBV immediate-early protein ZE-
BRA by inhibiting ZEBRA function, resulting in inhibition
of EBV reactivation (Mannick et al., 1994). TPA induces
EBV reactivation in most EBV-infected cell lines (zur
Hausen et al., 1978). We found that TPA down-regulates
constitutive iNOS mRNA expression and induces EBV
reactivation (Gao et al., 1999, 2001). NO also inhibits EBV
superinfection of Raji cells (Kawanishi, 1995). Our
present study indicated that a NOS inhibitor L-NMMA
induced the expression of EA-D protein rather than the
immediate-early BZLF1 protein ZEBRA in P3HR-1 cells. It
seems likely that NO generated from L-Arg prevents EBV
replication by inhibiting EBV DNA amplification during
the lytic phase of the life cycle (Kawanishi, 1995). These
results indicate a possibility that EBV reactivation is
controlled by NO at multiple steps of the reactivation
cascade. We observed that EBV DNA copy number in
EBV-infected GT38 cells decreased in the long-term-
cultured cells (Kanamori et al., 2001). The long-term-
cultured cells exhibited a higher level of iNOS mRNA
expression than did those short-term-cultured cells (Gao
et al., 2001). These results suggest that NO regulates not
only EBV reactivation but also maintenance of the EBV
genome in infected cells. One can speculate that NO is
a natural defense mechanism for EBV-targeted cells.
It is a remarkable point that the L-Arg concentration
which inhibits EBV reactivation is within the range of
physiological concentrations. L-Arg is one of the most
versatile, immunoregulating amino acids for animal cells.
L-Arg enhanced natural-killer (NK) and lymphokine-acti-
vated killer (LAK) cell activity (Park et al., 1991). The
enhancement of human NK and LAK cell activity by
increased, but yet physiological, levels of L-Arg could be
useful in therapy of many immunosuppressed states,
including congenital, iatrogenic (posttransplant), and in-
fectious immunodeficiencies (AIDS) which may be ac-
companied by the fatal proliferation of EBV-transformed
immunoblasts (Penn, 1987; Rickinson et al., 1992), in
which depressed NK cell activity is an important compo-
nent of the disease pathophysiology. The effect of L-Arg
in generating NO could be tested in EBV-associated
diseases accompanied with EBV reactivation such as
chronic active EBV infection (Rickinson, 1986), oral hairy
leukoplakia (Greenspan et al., 1985), and EBV-associated
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malignant disorders with high EBV antibody titers (Henle
et al., 1979).
In conclusion, we have demonstrated that EBV reacti-
vation in P3HR-1 cells is inhibited by increasing L-Arg
levels within a normal physiological range. The inhibitory
effect of L-Arg is consistent with a conclusion that NO
generated from the added L-Arg plays a regulatory role
in EBV reactivation. In addition, we have extended our
understanding of the mechanism of EBV reactivation and
suggested natural defense mechanisms against EBV in-
fection by L-Arg in generating NO.
MATERIALS AND METHODS
Cells
EBV-positive BL cell lines P3HR-1 (Hinuma et al.,
1967), EB1 (Epstein and Barr, 1964, 1965), Raji (Pulvertaft,
1965), an epithelial cell line from a human gastric tissue,
GT38 (Tajima et al., 1998), and a lymphoblastoid cell line
from peripheral blood of a patient with atopic dermatitis
(Ohnishi et al., 1997) were used. P3HR-1, EB1, and OB
cells were cultured in Dulbecco’s modified Eagle’s me-
dium (DMEM; Nissui, Tokyo, Japan) containing 0.4, 0.7,
0.9, or 1.2 mM L-Arg at 37 or 33°C. Raji and GT38 cells
were grown in RPMI 1640 medium (Nissui) at 37°C. Both
media were supplemented with 10% heat-inactivated fe-
tal bovine serum, penicillin (100 U/ml), and streptomycin
(100 g/ml). All cells were incubated in an atmosphere of
95% air and 5% CO2. Viable cell numbers were counted
by trypan blue dye exclusion method.
Reagents
L()-Arg monohydrochloride (Nacalai Tesque Inc.,
Kyoto, Japan) was diluted in H2O to create a 50 mM stock
solution. L-NMMA (Calbiochem, San Diego, CA) was
diluted in H2O to create a 200 mM stock solution.
Immunofluorescence for the detection of EA
Cells were washed with phosphate-buffered saline
(PBS) and spotted on glass slides, dried, and fixed in
acetone for 10 min at room temperature. The smears
were incubated with the first antibody, which was a
serum (anti-EA titer, 1:1280) from a patient with chronic
active EBV infection, at 37°C for 45 min, washed in PBS,
and incubated with the FITC-conjugated anti-human IgG
(Cappel) at 37°C for 45 min. The slides were washed and
mounted in 1:1 glycerol/PBS and examined under a flu-
orescence microscope. At least 1000 cells were counted
to determine the percentage of EA-positive cells.
Assay of infectious virus in P3HR-1 cells
P3HR-1 cells were cultured for 7 days at 33°C. The
culture fluids were assayed for production of infectious
virus on EA induction of Raji cells as described previ-
ously (Sairenji and Hinuma, 1973; Sairenji et al., 1985).
Preparation of RNA
The total RNA from cells was prepared by an ISOGEN
kit (Nippongene Inc., Tokyo, Japan) according to the
manufacturer’s protocol as described previously (Gao et
al., 1999). Briefly, cells were lysed in the ISOGEN solu-
tion. The homogenate of the cell lysate was kept at room
temperature for 5 min and then treated with chloroform
for 3 min. The mixture was centrifuged at 12,000 g for 15
min at 4°C. The upper aqueous phase was collected,
treated with 0.5 ml isopropanol for 10 min, and centri-
fuged for 10 min at 4°C. The RNA pellet was washed with
75% ethanol and dried after centrifugation. The RNA was
dissolved in diethylpyrocarbonate-treated water and
stored at 20°C. All RNA samples had an OD260/OD280
ratio  1.50.
RT-PCR analysis
Total RNA (1 g) was converted to cDNA using
random hexamers (2.5 M, from RNA PCR core kit,
Perkin–Elmer, Branchburg, NJ) as primers with murine
leukemia virus reverse transcriptase (2.5 U/l) in a
buffer compatible with PCR containing the following: 5
mM MgCl2, 50 mM NaCl, 10 mM Tris–HCl, RNase
inhibitor (1 U/ml), and 1 mM each dNTP (dATP, dGTP,
dCTP, and dTTP). A final volume of 20 ml was used.
The reaction mixture was incubated 42°C for 1 h,
heated to 94°C for 5 min to denature the reverse
transcriptase, and cooled on ice for 5 min. As primers
for PCR, two oligonucleotides for the human iNOS
were chosen according to the sequence of GenBank
Accession No. X73029. The sequence of sense and
antisense primers used for amplification of specific
human iNOS cDNA are as follows: sense primer, 5-
CTGTCCTTGGAAATTTCTGTT-3; antisense primer, 5-
GTGATGGCCGACCTGATGTTGC-3; to amplify a
729-bp nucleotide product. The oligonucleotides of the
“housekeeping gene” human -tubulin (GenBank Ac-
cession No. V0059) were designed as 5-TGGATCTA-
GAACCTGGGACCAT-3 (sense primer) and 5-ACCAT-
GTTGACTGCCAACTTGC-3 (antisense primer) to am-
plify a 577-bp product. The primers were synthesized
by Pharmacia-Japan Co., Tokyo, Japan. Of a total of 20
l, 3 l of the resulting cDNA was PCR amplified in 15
l reactions. The PCR conditions were 60 s of dena-
turation at 95°C, 60 s of annealing at 62°C, and 60 s of
extension of 72°C for 36 cycles. The amplified PCR
products were analyzed after electrophoresis in a 1.2%
agarose gel, blot-transferred to Hybond-N nylon
membrane (Amersham, Buckinghamshire, U.K.), and
UV-autocross-linked. The membranes for iNOS and
tubulin were prehybridized with prehybridization buffer
and then hybridized with the labeled probes. The hy-
bridized PCR product was visualized by autoradiogra-
phy.
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Northern blot analysis
Northern blot analysis was carried out by the method
described previously (Gao et al., 1999). Total RNA sam-
ples were denatured in 50% formamide and 2.2 M form-
aldehyde at 57°C for 15 min. Aliquots containing 20 g of
total RNA were loaded into a 1% agarose gel containing
2.2 M formaldehyde and electrophoresed with a running
buffer containing 50 mM MOPS acetate (pH 7.0), 10 mM
sodium acetate, and 1 mM EDTA. The RNA was then
transferred to Hybond-N membranes by capillary trans-
fer and UV auto-cross-linked.
Hybridization
Membranes were prehybridized in 5 SSPE (1
SSPE 180 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA, pH
7.4), 50% formamide, 5 Denhardt’s solution, 1% sodium
dodecyl sulfate (SDS), and 200 g salmon sperm DNA/
ml, for 6 h at 42°C. The prehybridization solution was
then replaced with fresh hybridization solution contain-
ing the labeled probe at a final concentration of 1  106
cpm/ml and hybridization was continued for 24 h at 42°C.
The blots were washed three times at 65°C in 1 SSPE,
0.1% SDS for 10 min. The blots were exposed to Kodak
X-AR film (Eastman Kodak Co., Rochester, NY) at 80°C
for 1–3 days. Relative mRNA levels were quantitated by a
phosphor image system (Molecular imager, Nippon Bio-
rad Laboratories KK, Tokyo, Japan). After hybridization
with iNOS probe, a Northern blot membrane was
stripped by boiling 5 mM EDTA/0.1% SDS. It was then
rehybridized with a probe specific for glyceraldehyde-3-
phosphate-dehydrogenase (GAPDH) (Mellinghoff et al.,
1991) to control for variations in the amount of RNA per
lane.
Western blot analysis
Ten million cells were washed twice with ice-cold PBS
and treated with 10% trichloroacetic acid on ice for 15
min. Then they were collected in a microcentrifuge tube
and solubilized in the buffer solution containing 125 mM
Tris–HCl (pH 6.8), 2.3% (w/v) lithium dodecyl sulfate, 10%
(w/v) glycerol, 5% (v/v) 2-mercaptoethanol, 10 g/ml
bromphenol blue, boiled for 5 min, and stored at 80°C
until use. Western blot analysis was carried out on pro-
tein samples (40–50 g per lane) which had been sep-
arated electrophoretically and transferred onto polyvi-
nylidene difluoride membrane (Millipore Co., Bedford,
MA), using a semidry transfer blot system. Equal
amounts of protein were blotted onto the membranes, as
confirmed by Coomassie brilliant blue R-250 dye stain-
ing. The nonspecific reaction was blocked by soaking
the membranes for 2 h in PBS–Tween 20 solution con-
taining 5% nonfat dry milk powder (blocking buffer) at
room temperature. The blocked membranes were then
incubated overnight at 4°C with anti-ZEBRA or anti-EA-D
monoclonal antibodies in blocking buffer. Blots were
washed in blocking buffer three times and then incu-
bated with the labeled rabbit anti-mouse IgG second
antibodies in the identical blocking buffer for 1 h, fol-
lowed by the chemiluminescence reaction and exposure
to X-ray film.
NOx (NO2
  NO3
) production
P3HR-1 cells were cultured in DMEM with 1.2 mM
L-Arg or 1.2 mM L-lysine at 37 or 33°C. After incubation,
the amounts of NOx released into the culture medium
were determined by the modified Griess method (Green
et al., 1982; Wood et al., 1990). Briefly, 100 l of culture
medium was mixed with 150 l of Griess reagent (1%
sulfanilamide/0.1% naphthylethylenediamine dihydro-
chloride/5% H3PO4). After incubation at 25°C for 10 min,
absorbance at 535 nm was determined in a Hitachi
U-2000 spectrophotometer (Hitachi, Tokyo, Japan).
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